secwatch.observer — SEC 8-K summary
======================================

Issuer:     TriSalus Life Sciences, Inc. (TLSI)
CIK:        0001826667
Form:       8-K
Filed at:   2024-01-25T23:59:59+00:00
Accession:  0001104659-24-006749
Event type: other_material
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

TriSalus Life Sciences grants CFO Sean Murphy option for 125,000 shares at $9.28
--------------------------------------------------------------------------------

- Granted on Jan 24, 2024, under the 2023 Equity Incentive Plan.
- Exercise price of $9.28 per share, equal to grant-date market price.
- Vests 25% on first anniversary, remaining 75% in 36 equal monthly installments.
- Contingent on Mr. Murphy's continuous service through each vesting date.
- Award recognizes CFO's 2023 performance and aligns long-term incentives.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1826667/000110465924006749/0001104659-24-006749-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1826667/000110465924006749/tm244105d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-006749

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer